Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon Dec 02, 2020 11:15am
130 Views
Post# 32017867

RE:RE:The investors who participated in the PP.....

RE:RE:The investors who participated in the PP.....
MarketMoney wrote: Is anyone else refreshing SEDAR and tsx szls page once in a while....haha this time I want to make sure I don't miss the opportunity to buy extra discount shares before the rest realize what happen :-)


Yes, for a stock thats the most watched Healthcare one on SH, it is certainly slow moving vis a vis buying. I get the feeling that most investors are waiting for the spike up so they can jump in at that time at a slightly higher price but at least assured that its heading in the right direction. The problem over the past few years was Tripp's overly enthusiastic speculations read: $30 million by years end etc and now investors once burned, want to see concrete numbers and material NRs to back up any claims. There is obviously some doubt in the minds of some as far as Aristotle is concerned - will it have the impact we all think it will, will it be accepted and embraced immediately as a medical break through, will hospitals and medical networks endorse it out of the gate, Oncore etc. etc. If otherwise, investors would be scooping up shares now at seemingly low prices as it sits on the cusp of being announced.

All this to say that as a long I am optimistic that liquid biopsy cancer testing will have a strong market impact and that our Covid testing network is perfectly timed to assist Aristotle - the dominos have lined up well for us marketing wise positioning Aristotle better than if ever would have been without Covid. I guess we are about to find out shortly - bring on that hospital affiliation Clarus alluded to and get the ball rolling - we are definitely overdue for something from Tripp other than of the closing pp variety.
<< Previous
Bullboard Posts
Next >>